The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies. In an ...
The proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor evolocumab reduces the risk of major adverse cardiovascular events (MACE) among patients with a previous myocardial infarction, ...
Myocardial ischemia is a drop in blood flow to the heart. Myocardial infarction, or heart attack, occurs when death or damage occurs in the muscle tissue of the heart due to low blood supply. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results